Stock Events

Stock Events

Niki BioSolutions 

$6.80
48
+$0.18+2.72% 14:37 Today

Statistics

Day High
7.16
Day Low
6.6
52W High
25.9
52W Low
6
Volume
8,910
Avg. Volume
89,649
Mkt Cap
5.54M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

20NovExpected
Q1 2026
Q2 2026
Next
0
0.33
0.67
1
Expected EPS
N/A
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
0Revenue
-4.27MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow NIKI. It's not an investment recommendation.
NVIDIA
9
NVDA
Microsoft
8
MSFT
Apple
7
AAPL
Amazon
7
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Gilead Sciences
GILD
Mkt Cap180.64B
Gilead Sciences focuses on infectious diseases, a key area for Aptorum, making them direct competitors in developing treatments.
Merck
MRK
Mkt Cap366B
Merck operates in various therapeutic areas including infectious diseases, competing with Aptorum's research and development focus.
Pfizer
PFE
Mkt Cap159.36B
Pfizer has a broad portfolio including anti-infectives, directly competing with Aptorum's infectious disease projects.
Abbvie
ABBV
Mkt Cap451.46B
AbbVie, with its research in diverse therapeutic areas, competes with Aptorum, especially in the infectious disease sector.
Novartis
NVS
Mkt Cap292.35B
Novartis competes across multiple therapeutic areas, including those targeted by Aptorum, making them a key competitor.
Astrazeneca
AZN
Mkt Cap252.33B
AstraZeneca has a strong focus on innovation in healthcare, including infectious diseases, positioning them as competitors to Aptorum.
Bristol-Myers Squibb
BMY
Mkt Cap136B
Bristol Myers Squibb's diverse biopharmaceutical products compete with Aptorum's therapeutic development efforts.
AMGEN
AMGN
Mkt Cap233.78B
Amgen's broad focus on biotechnological medicines puts them in competition with Aptorum's diverse therapeutic pipeline.
Regeneron Pharmaceuticals
REGN
Mkt Cap81.77B
Regeneron Pharmaceuticals, known for its innovative treatments, competes with Aptorum in developing novel therapies.
Vertex Pharmaceuticals
VRTX
Mkt Cap137.3B
Vertex Pharmaceuticals' focus on creating transformative medicines for serious diseases competes with Aptorum's mission and pipeline.

About

Niki BioSolutions Inc, formerly Aptorum Group Ltd is a clinical-stage biopharmaceutical company. It is engaged in the discovery, development, and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. Its project pipeline includes SACT-1, a repurposed drug for the treatment of neuroblastoma, and ALS-4, a small molecule for the treatment of bacterial infections caused by Staphylococcus aureus, including but not limited to Methicillin-resistant Staphylococcus aureus (MRSA).
Show more...
CEO
Chung Yuen Huen
Employees
2
Country
Cayman Islands
ISIN
US6539421023
WKN
000A3D7B2

Listings

STU
DE
APM.STU
MU
DE
APM.MU
XETRA
DE
APM.XETRA
XNAS
US
NIKI

0 Comments

Share your thoughts

FAQ

What is Niki BioSolutions stock price today?▼
The current price of NIKI is $6.80 USD — it has increased by +2.72% in the past 24 hours. Watch Niki BioSolutions stock price performance more closely on the chart.
What is Niki BioSolutions stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Niki BioSolutions stocks are traded under the ticker NIKI.
What is Niki BioSolutions market cap?▼
Today Niki BioSolutions has the market capitalization of 5.54M
When is the next Niki BioSolutions earnings date?▼
Niki BioSolutions is going to release the next earnings report on November 20, 2026.
What were Niki BioSolutions earnings last quarter?▼
NIKI earnings for the last quarter are 0 USD per share, whereas the estimation was N/A USD resulting in a N/A surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Niki BioSolutions revenue for the last year?▼
Niki BioSolutions revenue for the last year amounts to 0 USD.
What is Niki BioSolutions net income for the last year?▼
NIKI net income for the last year is -4.27M USD.
How many employees does Niki BioSolutions have?▼
As of September 02, 2026, the company has 2 employees.
In which sector is Niki BioSolutions located?▼
Niki BioSolutions operates in the Health & Wellness sector.
When did Niki BioSolutions complete a stock split?▼
Niki BioSolutions has not had any recent stock splits.
Where is Niki BioSolutions headquartered?▼
Niki BioSolutions is headquartered in Princeton, Cayman Islands.